Benzinga | Jul 14, 2021 11:42AM EDT

CohBar Stock Slumps As Data From NASH, Obesity Candidate Delayed By Almost Two Months

* CohBar Inc (NASDAQ:CWBR) has updated the timing for releasing Phase 1a/1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity.

* The process of data entry and final validation, which must be concluded before database lock, is ongoing.

* Once the database is locked, external biostatisticians will have access to the unblinded data from the study, enabling them to perform the data analysis and generate the final output.

* The company currently expects to release topline data before Labor Day 2021.

* In Q1 2021 earnings release, the company expected the data in early July 2021.

* Price Action: CWBR shares are down 17.4% at $1.14 during the market session on the last check Wednesday.